NCT01709825

Brief Summary

The purpose of this study is to determine if daily consumption of a probiotic in the period before, during and after academic exams will help maintain digestive and immune health and quality of life of undergraduate students.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
583

participants targeted

Target at P75+ for not_applicable healthy

Timeline
Completed

Started Sep 2012

Shorter than P25 for not_applicable healthy

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2012

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

October 11, 2012

Completed
7 days until next milestone

First Posted

Study publicly available on registry

October 18, 2012

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2012

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2013

Completed
Last Updated

January 29, 2015

Status Verified

January 1, 2015

Enrollment Period

3 months

First QC Date

October 11, 2012

Last Update Submit

January 27, 2015

Conditions

Keywords

probioticscoldfluimmune functionmicrobiota

Outcome Measures

Primary Outcomes (3)

  • Proportion of days without cold/flu

    The intensity of cold/flu symptoms (running/congested nose, stiffness or chills, headache, cough, fatigue, fever, sore throat, achiness, and ear discomfort)will be scored as 0 (not experiencing) to 3 (severe). The symptom intensity from the 9 cold/flu symptoms will be summed to obtain a symptom intensity score. A symptom intensity score of \>6 will be designated as a day of cold. The mean proportion of days without a cold/flu will be compared between each probiotic and the placebo.

    over 6 weeks

  • Microbiota Study

    * Microbial diversity measured by DGGE profiling (detect large distortions) * qPCR to quantify treatment effects on specific bacteria

    Change in microbiota from pre-baseline to on average week 4

  • Digestive Health

    * Gastrointestinal symptoms (gas, bloating, diarrhea, etc.) * Bowel habits (bowel movement frequency and consistency) * Measures of quality of life (physical functioning, general health, bodily pain, vitality and social functioning)

    Daily for 7 weeks

Secondary Outcomes (1)

  • Immune Health

    Measured at pre-baseline and on average week 4

Study Arms (4)

Sugar Pill

PLACEBO COMPARATOR

Sugar Pill will be taken as a capsule once daily for 6 weeks.

Dietary Supplement: Sugar Pill

Probiotic- Bifidobacterium bifidum

EXPERIMENTAL

Bifidobacterium bifidum (Supplement A) will be taken as a capsule once daily for 6 weeks.

Dietary Supplement: Probiotic- Bifidobacterium Bifidum

Probiotic- Lactobacillus helveticus

EXPERIMENTAL

Lactobacillus helveticus (Supplement B) will be taken as a capsule once daily for 6 weeks.

Dietary Supplement: Probiotic- Lactobacillus helveticus

Probiotic- Bifidobacterium longum ss. Infantis R0033

EXPERIMENTAL

Bifidobacterium longum ss. Infantis R0033 (Supplement C)will be taken as a capsule once daily for 6 weeks.

Dietary Supplement: Probiotic- Bifidobacterium longum ss. Infantis R0033

Interventions

Bifidobacterium bifidum R0071 will be taken as a capsule once daily for 6 weeks.

Also known as: Bifidobacterium bifidum, Supplement A
Probiotic- Bifidobacterium bifidum
Sugar PillDIETARY_SUPPLEMENT

Sugar Pill (Sucrose) will be taken as a capsule once daily for 6 weeks.

Also known as: Sucrose
Sugar Pill

Lactobacillus helveticus R0052 will be taken as a capsule once daily for 6 weeks.

Also known as: Lactobacillus helveticus, Supplement B
Probiotic- Lactobacillus helveticus

Bifidobacterium longum ss. Infantis R0033 (Supplement C) will be taken as a capsule once daily for 6 weeks.

Also known as: Bifidobacterium longum ss. Infantis R0033, Supplement C
Probiotic- Bifidobacterium longum ss. Infantis R0033

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • To participate in the study you must:
  • be 18 years of age or older.
  • be a healthy full-time undergraduate at the University of Florida.
  • be willing to complete daily questionnaires form via computer.
  • be willing to discontinue any immune-enhancing dietary supplements (e.g., prebiotics and fiber supplements, probiotics, echinacea, fish oil, vitamin E \>400% of the RDA or \>60 mg/day).
  • be willing to take the probiotic capsule daily of 6 weeks.
  • have had at least one cold in the last 12 months.
  • have at least 1 final during the scheduled exam week.
  • have daily access to the Internet.

You may not qualify if:

  • To participate in the study you must NOT:
  • be a current smoker.
  • have chronic allergies involving the upper respiratory tract.
  • have had immunosuppressive illness or treatment within the last year.
  • have received antibiotic therapy in the past two months.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Florida

Gainesville, Florida, 32611, United States

Location

Related Publications (2)

  • Langkamp-Henken B, Rowe CC, Ford AL, Christman MC, Nieves C Jr, Khouri L, Specht GJ, Girard SA, Spaiser SJ, Dahl WJ. Bifidobacterium bifidum R0071 results in a greater proportion of healthy days and a lower percentage of academically stressed students reporting a day of cold/flu: a randomised, double-blind, placebo-controlled study. Br J Nutr. 2015 Feb 14;113(3):426-34. doi: 10.1017/S0007114514003997. Epub 2015 Jan 21.

  • Culpepper T, Christman MC, Nieves C Jr, Specht GJ, Rowe CC, Spaiser SJ, Ford AL, Dahl WJ, Girard SA, Langkamp-Henken B. Bifidobacterium bifidum R0071 decreases stress-associated diarrhoea-related symptoms and self-reported stress: a secondary analysis of a randomised trial. Benef Microbes. 2016 Jun;7(3):327-36. doi: 10.3920/BM2015.0156. Epub 2016 Feb 3.

MeSH Terms

Conditions

Common ColdInfluenza, Human

Interventions

SugarsSucroseISL2 protein, Lactobacillus helveticus

Condition Hierarchy (Ancestors)

Respiratory Tract InfectionsInfectionsPicornaviridae InfectionsRNA Virus InfectionsVirus DiseasesRespiratory Tract DiseasesOrthomyxoviridae Infections

Intervention Hierarchy (Ancestors)

CarbohydratesDisaccharidesOligosaccharidesPolysaccharides

Study Officials

  • Bobbi Langkamp-Henken, PhD, RD

    University of Florida

    PRINCIPAL INVESTIGATOR
  • Wendy Dahl, PhD, RD

    University of Florida

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 11, 2012

First Posted

October 18, 2012

Study Start

September 1, 2012

Primary Completion

December 1, 2012

Study Completion

January 1, 2013

Last Updated

January 29, 2015

Record last verified: 2015-01

Locations